Dynogen Pharmaceuticals Inc. of Waltham said it licensed a late-stage drug candidate from Mitsubishi Pharma Corp. Terms weren't disclosed. The compound, pumosetrag, is thought to be helpful to patients suffering from a variety of gastrointestinal conditions, such as irritable bowel syndrome. Dynogen, a privately held firm, said it plans to start new clinical trials with pumosetrag next year. Mitsubishi, part ...